By using an immunohistochemical-based approach in breast carcinomas, Filardo and coworkers originally demonstrated that the expression of GPER correlates with clinical and pathological biomarkers of poor outcome as HER-2, increased tumor size and metastasis (59). The gene discussed is ERBB2; the disease is breast carcinoma.